Quipt Home Medical Corp.

Quipt Home Medical Corp. specializes in delivering a broad array of essential medical devices and supplies directly to patients' homes across the United States, encompassing both respiratory and durable medical equipment. The company focuses on supporting individuals grappling with chronic illnesses, particularly those affected by cardiac and pulmonary conditions, sleep apnea, limited mobility, and other persistent health challenges. Their extensive product catalog includes diverse therapeutic and mobility aids, such as oxygen concentrators, ventilators, CPAP and BiPAP devices (along with masks and accessories), nebulizers, humidifiers, hospital beds, patient lifts, wheelchairs, walkers, canes, bariatric solutions, bathroom safety products, and wound care items. Beyond equipment, they provide comprehensive services like home-based treatments for sleep apnea and chronic obstructive pulmonary disease (COPD), logistical support for healthcare delivery, and oxygen therapy, with convenient home and hospital delivery options. Established in 1993 as Protech Home Medical Corp., the company rebranded as Quipt Home Medical Corp. in May 2021 and maintains its corporate headquarters in Wilder, Kentucky.

Quipt Home Medical Corp. trades as QIPT.TO on TSX. The company is classified in Healthcare / Medical - Devices and reports in CAD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $245.36M of revenue and -$10.70M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Quipt Home Medical Corp. can be compared against peers such as Cannabix Technologies Inc., Cardiol Therapeutics Inc., Grown Rogue International Inc., Helix BioPharma Corp., HLS Therapeutics Inc., Cannara Biotech Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $221.44M, beta of 0.49, and return on equity of -7.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

QIPT.TO currently shows total debt of $118.79M and beta of 0.49. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://quipthomemedical.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.